Trials / Completed
CompletedNCT06191614
DEXINEURO® Tab on Blood Glucose Reduction in Patients With Type 2 Diabetes Accompanied by Diabetic Peripheral Neuropathy
Multi-center, Single-group, Prospective Observational Study to Evaluate the Efficacy of DEXINEURO Tab on Blood Glucose Reduction in Type 2 Diabetic Patients With Diabetic Peripheral Neuropathy
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 528 (actual)
- Sponsor
- Hanlim Pharm. Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy of DEXINEURO® tab on blood glucose reduction and assess the interaction with concomitantly administered insulin or oral antidiabetic agents in patients with type 2 diabetes accompanied by diabetic peripheral neuropathy.
Detailed description
This clinical trial is a multi-center, single-group, prospective observational study conducted to investigate the interaction with concomitant insulin or oral antidiabetic agents and assess the influence on blood glucose reduction when administering DEXINEURO® tab to patients with type 2 diabetes and diabetic peripheral neuropathy.
Conditions
Timeline
- Start date
- 2022-05-19
- Primary completion
- 2023-06-30
- Completion
- 2023-06-30
- First posted
- 2024-01-05
- Last updated
- 2024-02-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06191614. Inclusion in this directory is not an endorsement.